Extended Data Fig. 1: Clinical trial design and enrollment.
From: Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
a, Trial design: Cyclophosphamide/fludarabine (Cy/Flu) chemotherapy is given on days -4, -3, and -2 (purple arrows). CAR-NKTs are infused on day 0 (green arrow). Tumor biopsy is performed at week 2 (blue arrow) and response evaluation with imaging at week 4 (range 4-6; orange arrow). Black arrows indicate clinic visits and peripheral blood analysis. b, Enrollment CONSORT flow diagram.
